Financial Contrast: Coloplast A/S (OTCMKTS:CLPBY) and Avantor (NYSE:AVTR)
by Teresa Graham · The Cerbat GemColoplast A/S (OTCMKTS:CLPBY – Get Free Report) and Avantor (NYSE:AVTR – Get Free Report) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.
Risk and Volatility
Coloplast A/S has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Avantor has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.
Insider & Institutional Ownership
95.1% of Avantor shares are held by institutional investors. 1.5% of Avantor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Coloplast A/S and Avantor’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coloplast A/S | 18.89% | 31.39% | 10.57% |
| Avantor | 5.28% | 12.40% | 5.11% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Coloplast A/S and Avantor, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coloplast A/S | 0 | 0 | 0 | 0 | N/A |
| Avantor | 0 | 3 | 12 | 0 | 2.80 |
Avantor has a consensus price target of $28.00, indicating a potential upside of 13.27%. Given Avantor’s higher possible upside, analysts plainly believe Avantor is more favorable than Coloplast A/S.
Valuation and Earnings
This table compares Coloplast A/S and Avantor”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coloplast A/S | $3.58 billion | 7.96 | $685.88 million | $0.33 | 39.94 |
| Avantor | $6.83 billion | 2.46 | $321.10 million | $0.39 | 63.38 |
Coloplast A/S has higher earnings, but lower revenue than Avantor. Coloplast A/S is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.
Summary
Avantor beats Coloplast A/S on 8 of the 13 factors compared between the two stocks.
About Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
About Avantor
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.